KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
基本信息
- 批准号:9243868
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-03 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:ADRBK1 geneAcquired Immunodeficiency SyndromeBindingCellsChinaClinical TrialsDevelopmentEtiologyFundingG protein coupled receptor kinaseGenomeGlutamic AcidGoalsHerpesviridae InfectionsHighly Active Antiretroviral TherapyHumanHuman Herpesvirus 8IndividualKaposi SarcomaLaboratoriesMalignant - descriptorMalignant NeoplasmsMediatingMesenchymal Stem CellsMicroRNAsModelingMolecularMorbidity - disease rateMulticentric Angiofollicular Lymphoid HyperplasiaMutagenesisMutateOrganPathologicPathway interactionsPatientsPreventionProteinsProto-Oncogene Proteins c-aktRoleSH3 DomainsSTAT3 geneSignal TransductionSiteSocietiesTherapeuticTimeTumor AngiogenesisTumor Cell InvasionViralVisceralangiogenesiscellular targetinginhibitor/antagonistinnovationinsightmortalitynovelnovel therapeutic interventionoverexpressionprimary effusion lymphomaprogramstherapeutic targettumortumorigenesis
项目摘要
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several cancers. Despite highly
active anti-retroviral therapy, Kaposi’s sarcoma (KS) remains as a dominant cancer in AIDS patients. The
hallmark pathological features of KS are excessive deregulation of angiogenesis and extreme invasiveness
manifested as multifocal tumors and involvement of visceral organs. Thus, understanding the molecular basis
of KSHV-induced angiogenesis and cell invasion could serve as the basis for developing novel therapeutic
approaches. Our US-China collaborative team funded by previous cycle of the US-China Program has made
significant progresses toward this goal by 1) developing a novel model of KSHV infection of human primary
mesenchymal stem cells (MSCs), in which KSHV induces angiogenesis, cell invasion, malignant
transformation and tumorigenesis closely mimicking human KS tumors;; 2) demonstrating the essential roles of
KSHV microRNAs (miRNAs) in KSHV-induced angiogenesis and cell invasion;; 3) identifying KSHV miR-K6-3p
as a pro-angiogenic miRNA that induces angiogenesis by targeting SH3 domain-binding glutamic acid-rich
protein (SH3BGR) to activate the STAT3 pathway;; and 4) demonstrating that KSHV miR-K3-5p promotes cell
invasion by targeting G-protein coupled receptor kinase 2 (GRK2) to activate the AKT signaling. We propose to
extend these exciting discoveries with the objective to further dissect the molecular mechanisms by which
KSHV miRNAs promote tumorigenesis by inducing angiogenesis and cell invasion, and to explore the
therapeutic application of these discoveries. The central hypothesis is that KSHV encodes specific miRNAs
to activate angiogenic and invasive pathways contributing to KSHV-induced tumorigenesis, and as a result,
targeting these pathways can effectively inhibit the development of KSHV-induced cancers. We will identify
KSHV miRNAs that mediate KSHV-induced angiogenesis and define the mechanisms of action (Aim 1);;
identify KSHV miRNAs that mediate KSHV-induced cell invasion and define the mechanisms of action (Aim 2);;
delineate the roles of pro-angiogenic and pro-invasive miRNAs in the development of tumors, and in tumor
angiogenesis and invasion (Aim 3);; and explore the therapeutic application of targeting angiogenic and
invasive pathways activated by KSHV miRNAs in KSHV-induced tumorigenesis (Aim 4). This application will
further reinforce the collaborative efforts of the two US and China teams with highly complementary expertise
to accelerate the advancements of the proposed project that are otherwise difficult to achieve by the individual
laboratories. The results from this project will be highly significant and innovative because they will, for the
first time, define the functions and mechanisms of action of KSHV miRNAs in tumor angiogenesis and invasion
in a genuine KS model, and identify novel targets for developing innovative therapeutic approaches. The study
will also establish a novel paradigm of oncogenesis mediated by viral subversion of the miRNA pathway, thus
providing insights into the oncogenesis of other cancers.
卡波西肉瘤相关疱疹病毒 (KSHV) 是多种癌症的病原体。
尽管积极的抗逆转录病毒治疗,卡波西肉瘤(KS)仍然是艾滋病患者的主要癌症。
KS 的标志性病理特征是血管生成过度失调和极度侵袭性
表现为多灶性肿瘤并累及内脏器官。因此,了解分子基础。
KSHV 诱导的血管生成和细胞侵袭的研究可以作为开发新疗法的基础
我们的美中合作团队在上一轮美中项目的资助下已经取得了进展。
通过 1) 开发人类原发性 KSHV 感染的新模型,在实现这一目标方面取得了重大进展
间充质干细胞 (MSC),其中 KSHV 诱导血管生成、细胞侵袭、恶性
转化和肿瘤发生密切模仿人类 KS 肿瘤;;2) 展示了的重要作用
KSHV microRNA (miRNA) 在 KSHV 诱导的血管生成和细胞侵袭中的作用;;3) 鉴定 KSHV miR-K6-3p
作为一种促血管生成 miRNA,通过靶向结合富含谷氨酸的 SH3 结构域来诱导血管生成
蛋白 (SH3BGR) 激活 STAT3 途径;;和 4) 证明 KSHV miR-K3-5p 促进细胞
我们建议通过靶向 G 蛋白偶联受体激酶 2 (GRK2) 激活 AKT 信号来入侵。
扩展这些令人兴奋的发现,旨在进一步剖析其分子机制
KSHV miRNAs通过诱导血管生成和细胞侵袭促进肿瘤发生,并探讨其作用机制
这些发现的治疗应用的核心假设是 KSHV 编码特定的 miRNA。
激活有助于 KSHV 诱导的肿瘤发生的血管生成和侵袭途径,因此,
我们将确定针对这些途径可以有效抑制 KSHV 诱导的癌症的发展。
KSHV miRNA 介导 KSHV 诱导的血管生成并定义作用机制(目标 1);;
鉴定介导 KSHV 诱导的细胞侵袭的 KSHV miRNA 并确定作用机制(目标 2);;
描述促血管生成和促侵袭 miRNA 在肿瘤发生和肿瘤发生中的作用
血管生成和侵袭(目标 3);并探索靶向血管生成和侵袭的治疗应用
KSHV miRNA 在 KSHV 诱导的肿瘤发生中激活的侵袭途径(目标 4)。
进一步加强中美两个专业知识高度互补的团队的合作
加速推进个人难以实现的拟议项目
该项目的结果将非常重要且具有创新性,因为它们对于
首次明确KSHV miRNA在肿瘤血管生成和侵袭中的功能和作用机制
在真正的 KS 模型中,并确定开发创新治疗方法的新目标。
还将建立一种由病毒颠覆 miRNA 通路介导的肿瘤发生的新范式,从而
提供对其他癌症的肿瘤发生的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shou-Jiang Gao其他文献
Shou-Jiang Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shou-Jiang Gao', 18)}}的其他基金
Citrulline-urea cycle in KSHV cellular transformation
KSHV 细胞转化中的瓜氨酸-尿素循环
- 批准号:
10634838 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy
微生物群对艾滋病-卡波西肉瘤发展和治疗的影响
- 批准号:
10753890 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity Supplement
N6-甲基腺苷 (m6A) 对 KSHV 复制的调节 - Diversity Supplement
- 批准号:
10533427 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9756364 - 财政年份:2018
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
- 批准号:
9906178 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
- 批准号:
10264784 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Targeting KSHV malignancies and persistent infection
针对 KSHV 恶性肿瘤和持续感染
- 批准号:
8943348 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9108377 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9257374 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in cellular transformation and tumorigenesis
KSHV microRNA 在细胞转化和肿瘤发生中的作用
- 批准号:
8728172 - 财政年份:2013
- 资助金额:
$ 20万 - 项目类别:
相似国自然基金
从CD4+、CD8+T细胞免疫活化分子及其上游调控因子表达探究健脾祛湿法治疗艾滋病免疫调节机制
- 批准号:81460716
- 批准年份:2014
- 资助金额:48.0 万元
- 项目类别:地区科学基金项目
HAART过程中HCV复制增强与肝细胞MAVS抗病毒通路的关系研究
- 批准号:81201286
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
HIV Tat-associated Sensory Neuropathy and the Contribution of Toll-like Receptor Pathway
HIV Tat 相关感觉神经病变和 Toll 样受体通路的贡献
- 批准号:
10838798 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
International Retroviral Symposium: Assembly, Maturation and Uncoating
国际逆转录病毒研讨会:组装、成熟和脱壳
- 批准号:
10762858 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)
COVID-19:外部质量保证计划监督实验室 (EQAPOL)
- 批准号:
10930677 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Investigating MHC-I downregulation by HIV-1 Nef using cryo-electron tomography with laser-based phase contrast
使用基于激光相差的冷冻电子断层扫描研究 HIV-1 Nef 对 MHC-I 的下调
- 批准号:
10607448 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别: